Group Award: Dual Effect of the Novel Syntetic SOD Mimetics in “A Cancer Therapy” 2000 - 2005 Investigator NIH CA42745: and Perfusion Effects in Cancer Therapy” “Hyperthermia 2000 - 2001 Principal Investigator AlzaPharmaceutucals, Inc.: of radioprotective effect of “Assessment amifostine on radiation-induced lung injury” 2001- 2003 Principal Investigator Varian Biosinergy Inc.: methods for prediction of “New induced lung injury” 2001 - 2003 Principal Investigator Aeolus Pharmaceuticals, Inc.: Effects of a novel superoxide dismutase “ mimetics on radiation-induced lung injury and tumor response” 2002 2004 Principal Investigator – Inc.: of radioprotective effect of KGF on “Assessment induced lung injury” 2002-2005 Investigator NIH CA69579-06: whole and regional lung injury in “Radiation-induced humans” 2004 2005 Co-Principal Investigator – Genzyme: antibodies as a means to reduce radiation induced “TGF-beta lung injury” 2002 2006 Principal Investigator – NIH 1R44-CA-96245: Protection/Cancer Therapy with an “Radiation SOD Mimetic” 7/1/03-7/31/07 Principal Investigator Mechanism of hypoxia mediated radiation lung injury NIH R01-CA98452-04 Total Project Costs: $1,369,800 2004-2007 Principal Investigator Biogen: Anti-TGFbeta small molecules to prevent radiation “Using therapy (RT) pneumonitis” 2004-2007 Co-Principal Investigator Amgen: evaluation of Palifyermin (rHuKGF) mediated “Preclinical esophageal radioprotection”
Group Award: “A Dual Effect of the Novel Syntetic SOD Mimetics in Cancer Therapy” 2000 - 2005 Investigator NIH CA42745: “Hyperthermia and Perfusion Effects in Cancer Therapy” 2000 - 2001 Principal Investigator AlzaPharmaceutucals, Inc.: “Assessment of radioprotective effect of amifostine on radiation-induced lung injury” 2001- 2003 Principal Investigator Varian Biosinergy Inc.: “New methods for prediction of lung injury” 2001 - 2003 Principal Investigator Aeolus Pharmaceuticals, Inc.: “ Effects of a novel superoxide dismutase mimetics on radiation-induced lung injury and tumor response” 2002 – 2004 Principal Investigator Inc.: “Assessment of radioprotective effect of KGF on lung injury” 2002-2005 Investigator NIH CA69579-06: “Radiation-induced whole and regional lung injury in humans” 2004 – 2005 Co-Principal Investigator Genzyme: “TGF-beta antibodies as a means to reduce radiation induced lung injury” 2002 – 2006 Principal Investigator NIH 1R44-CA-96245: “Radiation Protection/Cancer Therapy with an SOD Mimetic” 7/1/03-7/31/07 Principal Investigator Mechanism of hypoxia mediated radiation lung injury NIH R01-CA98452-04 Total Project Costs: $1,369,800 2004-2007 Principal Investigator Biogen: “Using Anti-TGFbeta small molecules to prevent radiation therapy (RT) pneumonitis” 2004-2007 Co-Principal Investigator Amgen: “Preclinical evaluation of Palifyermin (rHuKGF) mediated esophageal radioprotection” induced induced
CV_Vujaskovic0216.docx